单次HDR前列腺近距离治疗联合外照射后晚期毒性:前瞻性队列的临床与剂量学预测因素
该前瞻性队列纳入210例局限性前列腺癌患者,接受单次15 Gy HDR近距离治疗联合3DCRT 37.5 Gy/15次。中位随访41个月,晚期G2 GU和GI毒性分别为14.8%和5.2%,G3 GU为0%、GI为1%。直肠D1cc剂量和既往心血管病史是G≥2 GI毒性的独立预测因素。
要点
- 单次HDR-BT联合大分割EBRT的晚期G2 GU毒性14.8%、GI毒性5.2%,G3 GU为0%、GI为1%。
- 直肠D1cc剂量(HR11.56)和既往心血管病史(HR3.6)为G≥2 GI毒性独立预测因素。
- 未发现与晚期G≥2 GU毒性相关的结果因素。
核心结论
- 单次HDR-BT联合大分割EBRT治疗局限性前列腺癌的晚期GU和GI毒性发生率低。
- 既往心血管疾病和直肠受量(D1cc)与G≥2 GI毒性相关。
研究设计与样本
- 前瞻性队列研究,2012年1月至2017年5月纳入210例局限性前列腺癌患者。
- 治疗方案为HDR-BT单次15 Gy联合3DCRT 37.5 Gy/15次。
- 采用单因素和多因素逻辑回归分析变量对晚期毒性的影响。
主要发现
- 中位年龄71岁(56-82),低危12.4%、中危44.3%、高危41%。
- 中位前列腺体积28.4 cc,中位V100、V150、V200分别为98.2%、27%、7.4%。
- 中位尿道Dmax 113.5%,直肠D1cc 62.2%,直肠D2cc 54.2%。
- 中位随访41个月(5-75),晚期G2 GU和GI毒性分别为14.8%和5.2%。
- 晚期G3 GU和GI毒性分别为0%和1%。
关键数值与推荐
- 单因素分析:既往心血管合并症(p=0.042)、直肠D2cc(p=0.016)和D1cc(p=0.017)与G≥2 GI毒性相关。
- 多因素分析:直肠D1cc(HR11.56;95%CI 1.4-92.1;p=0.021)和既往心血管病史(HR3.6;95%CI 1-12.9;p=0.045)为G≥2 GI毒性独立预测因素。
- 单因素分析未发现与晚期G≥2 GU毒性相关的结果因素。
临床怎么用
- 采用单次HDR-BT联合大分割EBRT时,晚期GU和GI毒性发生率低。
- 应关注直肠D1cc剂量和患者既往心血管病史以预测G≥2 GI毒性风险。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe the genitourinary (GU) and gastrointestinal (GI) late toxicity profile and to analyse the clinical and dosimetry outcomes predictors of the combination of EBRT and high-dose-rate (HDR) prostate brachytherapy (BT) for localized prostate cancer. MATERIALS AND METHODS: Between January 2012 and May 2017, 210 patients were included in a prospective protocol. Treatment consisted in HDR-BT (15 Gy single fraction) plus 3DCRT (37.5 Gy/15 fractions). Univariate and multivariate logistic regressions were used to analyse the impact of variables on late toxicity. RESULTS: Median age was 71 (56-82), 12.4% of patients had low, 44.3% intermediate and 41% high-risk prostate cancer. Median prostate volume was 28.4 cc. Median V100, V150, V200 were 98.2%, 27% and 7.4% respectively. Median urethra Dmax, rectum D1cc and D2cc, were 113.5%, 62.2%% and 54.2% respectively. After a median follow-up of 41 months (5-75) late G2 GU and GI late toxicity was observed in 14.8% and 5.2% of patients respectively. Late G3 GU and GI toxicity occurred in 0% and 1% of patients respectively. There were no outcome correlations with late G ≥ 2 GU toxicity on univariate analysis. Previous cardiovascular comorbidity (p = 0.042), and dose to the rectum D2cc (p = 0.016) and D1cc (p = 0.017) were associated with G ≥ 2 GI toxicity. Multivariate analysis showed that rectum D1cc (HR11.56; 95%CI 1.4-92.1; p = 0.021) and prior history of cardiovascular disease (HR3.6; 95%CI 1-12.9; p = 0.045) remained independent predictors of G ≥ 2 GI toxicity. CONCLUSIONS: There is a low incidence of late GU and GI morbidity using single fraction HDR-BT and hypofractionated EBRT. Previous cardiovascular disease and dose to the rectum were observed to correlate with GI toxicity.
引用
- Büchser D, Casquero F, Espinosa JM, et al. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study. Radiother Oncol. 2019. PMID: 31015158. doi:10.1016/j.radonc.2019.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。